Neoplastic B-cell growth is impaired by HLA-G/ILT2 interaction

Leukemia

Volumn 26, Issue 8, 2012, Pages 1889-1892

  Naji, A ^a,b   Menier, C ^a,b   Maki, G ^a,b   Carosella, E D ^a,b   Rouas Freiss, N ^a,b  

^a SAINT LOUIS HOSPITAL   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HLA G ANTIGEN; ILT2 PROTEIN; PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; BURKITT LYMPHOMA; CANCER GROWTH; CELL CYCLE PROGRESSION; CELL METABOLISM; CELL PROLIFERATION; HUMAN; LETTER; LEUKEMIA CELL LINE; MULTIPLE MYELOMA; NEOPLASTIC B CELL GROWTH; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RAJI CELL;

ANTIGENS, CD; B-LYMPHOCYTES; CELL LINE, TUMOR; CELL PROLIFERATION; HLA-G ANTIGENS; HUMANS; LEUKEMIA, B-CELL; LYMPHOMA, B-CELL; MULTIPLE MYELOMA; PROTEIN BINDING; RECEPTORS, IMMUNOLOGIC;

EID: 84864872199     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.62     Document Type: Letter

References (10)

1. Hideshima T, Bergsagel PL, Kuehl WM, Anderson KC. Advances in biology of multiple myeloma: clinical applications. Blood 2004; 104: 607-618.
2. Dighiero G, Hamblin TJ. Chronic lymphocytic leukaemia. Lancet 2008; 371: 1017-1029.
3. Colonna M, Navarro F, Bellon T, Llano M, Samaridis J, Angman L et al. A common inhibitory receptor for major histocompatibility complex class I molecules on human lymphoid and myelomonocytic cells. J Exp Med 1997; 186: 1809-1818.
4. Carosella ED, Moreau P, Lemaoult J, Rouas-Freiss N. HLA-G: from biology to clinical benefits. Trends Immunol 2008; 29: 125-132.
5. Menier C, Guillard C, Cassinat B, Carosella ED, Rouas-Freiss N. HLA-G turns off erythropoietin receptor signaling through JAK2 and JAK2 V617F dephosphorylation: clinical relevance in polycythemia vera. Leukemia 2008; 22: 578-584.
6. McCubrey JA, Steelman LS, Abrams SL, Bertrand FE, Ludwig DE, Basecke J et al. Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy. Leukemia 2008; 22: 708-722.
7. Wang X, Yue P, Kim YA, Fu H, Khuri FR, Sun SY et al. Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR/raptor inhibitioninitiated, mTOR/rictor-independent Akt activation. Cancer Res 2008; 68: 7409-7418.
8. Martelli AM, Evangelisti C, Chappell W, Abrams SL, Basecke J, Stivala F et al. Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway. Leukemia 2011; 25: 1064-1079.
9. Ketroussi F, Giuliani M, Bahri R, Azzarone B, Charpentier B, Durrbach A. Lymphocyte cell-cycle inhibition by HLA-G is mediated by phosphatase SHP-2 and acts on the mTOR pathway. PLoS One 2011; 6: e22776.
10. Selmani Z, Naji A, Zidi I, Favier B, Gaiffe E, Obert L et al. Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells. Stem Cells 2008; 26: 212-222.